24h
Current
Min
1301.5
Max
1314.5
Recommendations | Neutral |
---|---|
12 Months Forecast | +27.9 upside |
Next Earnings | ٥ فبراير ٢٠٢٥ |
---|---|
Next Dividend date | ٩ يناير ٢٠٢٥ |
By Acuity
51%
49%
325 / 392 Ranking in Healthcare
Past performance is not a reliable indicator of future results.
١٥ نوفمبر ٢٠٢٤، ١٠:٢٨ ص UTC
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ١١:٤٤ ص UTC
GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness -- Update
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٥٠ ص UTC
GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine Demand
DJ
Read
٢٩ أكتوبر ٢٠٢٤، ٠١:٣٩ م UTC
GSK Buys Lupus Treatment For Up To $850 Million From Chimagen Biosciences
DJ
Read
١٥ نوفمبر ٢٠٢٤، ٠١:٠٨ م UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Read
١٥ نوفمبر ٢٠٢٤، ١٠:٣٤ ص UTC
Vaccine Sector Sell-Off Looks Overdone -- Market Talk
DJ
Read
١٥ نوفمبر ٢٠٢٤، ١٠:٢٩ ص UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Read
٧ نوفمبر ٢٠٢٤، ١١:٥٣ ص UTC
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
DJ
Read
٧ نوفمبر ٢٠٢٤، ١١:٣١ ص UTC
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
DJ
Read
٣١ أكتوبر ٢٠٢٤، ٠٧:٤٨ م UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٣:٠٤ م UTC
GSK's 3Q Results Are a Mixed Bag -- Market Talk
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٨:٢٢ ص UTC
GSK's Vaccine Weakness Is a Major Concern -- Market Talk
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:١٨ ص UTC
GSK Reiterates Guidance As HIV And Cancer Drug Demand Offset Vaccine Weakness -- MarketWatch
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٤ ص UTC
GSK PLC Expects to deliver Around Middle of Existing Annual Guidance Ranges
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٣ ص UTC
GSK PLC 3Q EPS 1.4p
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٢ ص UTC
GSK PLC Had Seen 2024 Sales Growth of 7% to 9%
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٢ ص UTC
GSK PLC Issues Dividend of 15p
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠١ ص UTC
GSK PLC Had Seen 2024 Core Earnings Per Share Growth of 10% to 12%
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠١ ص UTC
GSK PLC Had Seen 2024 Core Operating Pft Growth Between 11% and 13%
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠١ ص UTC
GSK PLC Backs 2024 View
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
Analysts Saw GSK PLC 3Q Net Pft GBP1.78B
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
Analysts Saw GSK PLC 3Q Turnover GBP8.00B
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Loss/Shr 1.4p
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Turnover GBP8.01B
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Adj EPS 49.7p
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Pre-items, Pretax Pft GBP2.65B
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Pretax Pft GBP64M
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Oper Pft GBP189M
DJ
Read
٣٠ أكتوبر ٢٠٢٤، ٠٧:٠٠ ص UTC
GSK PLC 3Q Net Loss GBP58M
DJ
Read
٢٩ أكتوبر ٢٠٢٤، ٠١:٢٤ م UTC
GSK Buys Lupus Treatment For Up To $850 Mln From Chimagen Biosciences
DJ
Read
By TipRanks
12 Months Forecast
Average 1,662.73 GBX 27.9%
High 2,610 GBX
Low 1,350 GBX
Based on 13 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.
By TipRanks
Neutral
13 ratings
4
Buy
7
Hold
2
Sell
Based on 13 analysts giving stock ratings to GlaxoSmithKline PLC - Dist in the past 3 months.
By Acuity
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
$